amifampridine and Multiple Sclerosis, Relapsing-Remitting
amifampridine has been researched along with Multiple Sclerosis, Relapsing-Remitting in 1 studies
Amifampridine: 4-Aminopyridine derivative that acts as a POTASSIUM CHANNEL blocker to increase release of ACETYLCHOLINE from nerve terminals. It is used in the treatment of CONGENITAL MYASTHENIC SYNDROMES.
Multiple Sclerosis, Relapsing-Remitting: The most common clinical variant of MULTIPLE SCLEROSIS, characterized by recurrent acute exacerbations of neurologic dysfunction followed by partial or complete recovery. Common clinical manifestations include loss of visual (see OPTIC NEURITIS), motor, sensory, or bladder function. Acute episodes of demyelination may occur at any site in the central nervous system, and commonly involve the optic nerves, spinal cord, brain stem, and cerebellum. (Adams et al., Principles of Neurology, 6th ed, pp903-914)
Research
Studies (1)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors
Authors | Studies |
---|---|
Mainero, C | 1 |
Inghilleri, M | 1 |
Pantano, P | 1 |
Conte, A | 1 |
Lenzi, D | 1 |
Frasca, V | 1 |
Bozzao, L | 1 |
Pozzilli, C | 1 |
Trials
1 trial available for amifampridine and Multiple Sclerosis, Relapsing-Remitting
Article | Year |
---|---|
Enhanced brain motor activity in patients with MS after a single dose of 3,4-diaminopyridine.
Topics: 4-Aminopyridine; Adult; Amifampridine; Axons; Cross-Over Studies; Double-Blind Method; Electromyogra | 2004 |